Atomoxetine is a non-stimulant medication primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults. Unlike traditional stimulant therapies, atomoxetine works by selectively inhibiting the reuptake of norepinephrine in the brain, which helps improve attention, focus, and impulse control without the high abuse potential associated with stimulant drugs. The development of atomoxetine began in the 1990s by Eli Lilly and Company as part of efforts to create effective ADHD treatments with a different mechanism of action than amphetamine-based stimulants. After extensive clinical trials demonstrating safety and efficacy, it was approved by the U.S. Food and Drug Administration in 2002 under the brand name Strattera, marking an important milestone in ADHD therapy as the first selective norepinephrine reuptake inhibitor specifically indicated for this condition.
